Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | MGAM | O43451 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | GPR3 | P46089 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.33 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.33 |
| ▸ | HTR3A | P46098 | 2/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1385432 | 0.81 | ALDH1A1 (0.42) | CYP1A2ALDH1A1MAPTHPGDGLA | |
| SCHEMBL19953245 | 0.78 | ALDH1A1 (0.36) | CYP1A2ALDH1A1MAPTHPGDGLA | |
| SCHEMBL302153 | 0.78 | EGFR (0.40) | CYP1A2ALDH1A1MAPTHPGDGLA | |
| SCHEMBL30198446 | 0.75 | CYP1A2 (0.60) | CYP1A2ALDH1A1MAPTHPGDGLA | |
| SCHEMBL1672650 | 0.75 | CYP1A2 (0.60) | CYP1A2ALDH1A1MAPTHPGDGLA | |
| SCHEMBL30527184 | 0.75 | CYP1A2 (0.60) | CYP1A2ALDH1A1MAPTHPGDGLA | |
| SCHEMBL692107 | 0.75 | CYP1A2 (0.45) | CYP1A2ALDH1A1MAPTHPGDGLA | |
| SCHEMBL6948594 | 0.75 | PDGFRB (0.53) | CYP1A2ALDH1A1MAPTMGAMPDGFRB | |
| SCHEMBL3856054 | 0.74 | ALDH1A1 (0.34) | CYP1A2ALDH1A1MAPTHPGDGLA | |
| SCHEMBL2659111 | 0.73 | NPC1 (0.44) | CYP1A2ALDH1A1MAPTHPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080076924-A1 | Piperazines as P2X7 antagonists | ABBOTT LABORATORIES | 2008-03-27 | — | — | US | claimed |
| WO-2008005368-A2 | PIPERAZINES AS P2X7 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2008-01-10 | — | — | WO | claimed |
| US-20080004288-A1 | Indazole Sulphonamide Derivatives | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | US | claimed |
| EP-1814863-A1 | INDAZOLE SULPHONAMIDE DERIVATIVES | AstraZeneca AB (SE) | 2007-08-08 | — | — | EP | claimed |
| WO-2006052190-A1 | INDAZOLE SULPHONAMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2006-05-18 | — | — | WO | claimed |
| CN-117295737-A | HPK1 antagonists and uses thereof | 林伯士萨顿公司 | 2023-12-26 | — | — | CN | disclosed |
| CN-116075513-A | Inhibitors of NEK7 kinase | 哈利亚治疗公司 | 2023-05-05 | — | — | CN | disclosed |
| EP-3116486-A2 | HYBRID IMMUNOGLOBULIN CONTAINING NON-PEPTIDYL LINKAGE | Capon, Daniel J. (US) | 2017-01-18 | — | — | EP | disclosed |
| WO-2015138907-A2 | HYBRID IMMUNOGLOBULIN CONTAINING NON-PEPTIDYL LINKAGE | CAPON DANIEL J (US) | 2015-09-17 | — | — | WO | disclosed |
| US-20080076924-A1 | Piperazines as P2X7 antagonists | ABBOTT LABORATORIES | 2008-03-27 | — | — | US | disclosed |
| WO-2008005368-A2 | PIPERAZINES AS P2X7 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2008-01-10 | — | — | WO | disclosed |
| US-20080004288-A1 | Indazole Sulphonamide Derivatives | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | US | disclosed |
| EP-1814863-A1 | INDAZOLE SULPHONAMIDE DERIVATIVES | AstraZeneca AB (SE) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006052190-A1 | INDAZOLE SULPHONAMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2006-05-18 | — | — | WO | disclosed |
| US-6235778-B1 | ANTICOAGULANTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004288-A1 | Indazole Sulphonamide Derivatives | SULT2A1, SULT1E1, SULT1A1 | CYP1A2 246/4885ALDH1A1 745/4885MAPT 3758/4885 |
| US-20080076924-A1 | Piperazines as P2X7 antagonists | P2RX7, P2RX1, P2RX2 | CYP1A2 452/4885ALDH1A1 852/4885MAPT 4184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.